An observational study in Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Stroke, Ischemic, sponsored by Jakub Antczak. Recruiting at 2 sites in Poland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.
Sponsored by Jakub Antczak · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Multiple Sclerosis with a site in Poland — 9 open to participants now, 30 under way, 18 of them phase 3. Multiple Sclerosis · Poland.
Among the 150 studies in Multiple Sclerosis with a site in Poland, this one is the 11th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2024, is one of 16 observational ones, reaches primary completion later than 14 of the 29 other live ones, and was the 142nd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 150 studies in Multiple Sclerosis with a site in Poland are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in Poland, United States, Slovakia
Ages 10–17
TG Therapeutics, Inc. · Sites in Poland, Bosnia and Herzegovina, Georgia and 3 more countries
Ages 18–65
Novartis Pharmaceuticals · Sites in Poland, United States, Argentina and 33 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Poland, Argentina, Brazil and 4 more countries
Ages 10–17
Celgene · Sites in Poland, United States, Australia and 4 more countries
Ages 18–70
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 41 · Phase 3 81 · Phase 4 10
First in 2002; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 310 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 435 across the 134 interventional studies, 387 across the 16 observational. Of the 118 that completed or were terminated, 89 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 150 have an industry lead sponsor. The 10 most frequent:
Jakub Antczak is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Jakub Antczak has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Multiple Sclerosis with a site in Poland that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT05961644Phase 3Institute of Psychiatry and Neurology, WarsawCladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). | 2027-06-30 |
| NCT06668649Jakub AntczakPolish Version Fatigue Severity Scale | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 150 studies in Multiple Sclerosis with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis and other diseases with profound effect on quality of life and professional and social functioning. Not infrequent it is misdiagnosed as sleepiness or other symptom. Fatigue severity scale is a time efficient and easy to apply instrument to assess the impact of fatigue on patient's life. The aim of this study is to validate the Polish-language version of the Fatigue Severity Scale.
Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis, post-polio syndrome, stroke, parkinsonism as well as in the chronic fatigue syndrome. It has profound effect on quality of life and professional and social functioning and in multiple sclerosis it is described as the worst symptoms by the 50% of patients. It is defined as the difficulty in initiating and maintaining a sustained mental or physical activity. Not infrequent it is misdiagnosed as sleepiness or other symptom. Fatigue severity scale (FSS) is a time efficient and easy to apply instrument to assess the impact of fatigue on patient's life. It has been translated and validated in Turkish, Russian, Hindi, Portuguese, and many other languages. FSS is a short, nine-item self-report questionnaire. Each item is a Likert scale, scored from one to seven, where seven refers to the most severely expressed aspect of fatigue. The aim of this study is to validate the Polish-language version of the Fatigue Severity Scale (pFSS). This version has been created according to widely accepted, respective standards, including translation by two independent native Polish-language speakers with acquired knowledge of English and backward translation by two independent native English-language speakers with acquired knowledge of Polish as well as with the pretesting on ten patients.
Participants will be recruited from the neurologic ambulatories and neurologic clinics of Jagiellonian University Medical College in Cracow and of Institute of Psychiatry and Neurology in Warsaw. Healthy controls will be recruited from personel of those facitlites as well as from the relatives of members of research team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Both sexes, aged 18 or older. The group will include 80 patients with multiple sclerosis, 80 patients with amyotrophic lateral sclerosis and 50 survivors of ischemic stroke
Diagnostic Test: Testing with Questionnaires
Both sexes, aged 18 or older. The group will include 100 healthy controls.
Diagnostic Test: Testing with Questionnaires
Testing with following Questionnaires: pFSS, Polish-language version of Modified Fatigue Impact Scale, Visual Analogue Scale of Fatigue, EQ-5D-5L (EuroQol-5 dimension) questionnaire, Beck Depression Inventory II. In randomly selected 30 patients and 20 controls questionnaires will be administered twice with two weeks interval to assess the test-retest reliability.
Internal Consistency
Consistency between particular items of Polish language version of the Fatigue Severity Scale will be evaluated using Cronbach alfa test. The score of the Polish language version of the Fatigue Severity Scale ranges between 9 and 63 with higher scores meaning a worse outcome.
Time frame: Through study completion, an average of 1 year
Validity
Validity will be tested by calculating the correlation of Polish language version of the Fatigue Severity Scale score with scores of Polish-language version of Modified Fatigue Impact Scale. The score of the Polish language version of the Fatigue Severity Scale ranges between 9 and 63 with higher scores meaning a worse outcome. The score of the Modified Fatigue Impact Scale ranges between 0 and 84 with higher scores meaning a worse outcome.
Time frame: Through study completion, an average of 1 year
Reliability
Reliability will be tested by calculating the correlation between Polish language version of the Fatigue Severity Scale scores from the 1st and 2nd administration in the randomly selected subgroup of patients and controls. The score of the Polish language version of the Fatigue Severity Scale ranges between 9 and 63 with higher scores meaning a worse outcome.
Time frame: Through study completion, an average of 1 year
Impact of fatigue on quality of life - index
Correlation between Polish language version of the Fatigue Severity Scale score and the index score of EQ-5D-5L (EuroQol-5 dimension) questionnaire. The score of the Polish language version of the Fatigue Severity Scale ranges between 9 and 63 with higher scores meaning a worse outcome. The index score of EQ-5D-5L (EuroQol-5 dimension) questionnaire ranges between -0.59 to 1 with higher scores indicating better outcome.
Time frame: Through study completion, an average of 1 year
Impact of fatigue on quality of life - visual analogue scale
Correlation between Polish language version of the Fatigue Severity Scale score and the visual analogue scale score of EQ-5D-5L (EuroQol-5 dimension) questionnaire. The score of the Polish language version of the Fatigue Severity Scale ranges between 9 and 63 with higher scores meaning a worse outcome. The visual analogue scale score of EQ-5D-5L (EuroQol-5 dimension) questionnaire ranges between 0 to 100 with higher scores indicating better outcome.
Time frame: Through study completion, an average of 1 year
Impact of fatigue on depression
Correlation between Polish language version of the Fatigue Severity Scale score and score of Beck Depression Inventory II. The score of the Polish language version of the Fatigue Severity Scale ranges between 9 and 63 with higher scores meaning a worse outcome. The score of the Beck Depression Inventory II ranges between 0 and 63 with higher scores indicating worse outcome.
Time frame: Through study completion, an average of 1 year
Difference in fatigue level between patients and controls
Difference in Polish language version of the Fatigue Severity Scale score between patients and controls. The score of the Polish language version of the Fatigue Severity Scale ranges between 9 and 63 with higher scores meaning a worse outcome.
Time frame: Through study completion, an average of 1 year
Plan to share: Yes — After the study is completed, the scans of collected questionnaires will be available upon request sent to the e-mail: jakub.antczak@uj.edu.pl
Supporting information: Study protocol
Time frame: After the study is completed for the period of ten years.
Access criteria: Researchers affiliated in institutions listed on clinicaltrials.gov.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 25 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jakub Antczak